Sunshine Biopharma Inc. (SBFM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8677818093
Sunshine Biopharma Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 36.31 m USD |
| Gross profit | 12.26 m USD |
| Operating income | -6.23 m USD |
| EBIT | -5.95 m USD |
| Net income | -5.98 m USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sunshine Biopharma Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
More stocks
- Peraso Inc. (PRSO)
- Brownie's Marine Group, Inc (BWMG)
- CIMG Inc. (CIMG)
- Propanc Biopharma, Inc. (PPCB)
- MUSTANG BIO, INC. (MBIO)
- Nexalin Technology, Inc. (NXL)
- NEXGEL, INC. (NXGL)
- Circle Energy, Inc./NV (CRCE)
- ALTEX INDUSTRIES INC (ALTX)
- Accustem Sciences Inc. (ACUT)
- KUSTOM ENTERTAINMENT, INC. (KUST)
- OCULUS INC. (OVTZ)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.